DM1 cohort recruitment completion in Q4 2025, topline data in mid-2026, and potential BLA filing for z-basivarsen in late ...
Sarepta prepares to present new data on Duchenne and limb-girdle muscular dystrophy gene therapy programs this week.
A New York panel has voted unanimously to recommend the state Medicaid program should pause coverage of a treatment for Duchenne muscular ...
In a setback for Sarepta Therapeutics, a New York panel has voted unanimously to recommend the state Medicaid program pause ...
Stocktwits on MSN
Why Sarepta Therapeutics Stock Is Rising Nearly 5% Premarket
Shares of Sarepta Therapeutics rose nearly 5% in early premarket trading on Wednesday as the company prepared to present new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback